a Cancer Clinical Trials and Research Unit , Beaumont Hospital and RCSI, Dublin 9 , Dublin , Ireland.
Expert Opin Biol Ther. 2018 Mar;18(3):251-262. doi: 10.1080/14712598.2018.1410132. Epub 2017 Dec 3.
The monoclonal antibody trastuzumab has improved the median disease free and overall survival of patients with early stage breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). Despite this advance, some patients experience cancer relapse and novel approaches are always needed. One such advance is the monoclonal antibody pertuzumab, which prevents dimerisation between members of the HER family of transmembrane glycoprotein receptors.
In this review, the authors analyse recent research which has focused on the development of new HER2 targeting agents for HER2-positive breast cancer, particularly pertuzumab, and its addition to trastuzumab and taxanes.
Pertuzumab has significantly improved disease control in patients with advanced HER2 positive breast cancer when added to chemotherapy and trastuzumab. Although pertuzumab has also increased response rates in the preoperative setting, this has not yet translated into increased overall survival. The authors believe that future research should focus on improvements in novel biomarkers to select patients for new treatments.
单克隆抗体曲妥珠单抗改善了人表皮生长因子受体 2（HER2）过表达的早期乳腺癌患者的中位无病生存期和总生存期。尽管取得了这一进展，但仍有部分患者出现癌症复发，因此需要不断探索新的治疗方法。曲妥珠单抗就是这样一种方法，它可以防止 HER 家族跨膜糖蛋白受体成员的二聚化。
在这篇综述中，作者分析了近期针对 HER2 阳性乳腺癌的新型 HER2 靶向药物的研究进展，尤其是曲妥珠单抗及其与紫杉醇和化疗药物联合应用的效果。
曲妥珠单抗与化疗和曲妥珠单抗联合应用显著改善了晚期 HER2 阳性乳腺癌患者的疾病控制。尽管曲妥珠单抗在术前治疗中也提高了缓解率，但尚未转化为总生存期的延长。作者认为，未来的研究应集中于新型生物标志物的改进，以选择适合新疗法的患者。
